Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENCNASDAQ:IMTXNASDAQ:RLAYNASDAQ:VECT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCFennec Pharmaceuticals$6.04-2.4%$6.02$3.96▼$10.07$166.67M0.32105,556 shs66,367 shsIMTXImmatics$5.00+2.7%$4.44$3.30▼$13.77$607.75M0.85653,491 shs349,344 shsRLAYRelay Therapeutics$3.33+7.4%$2.97$1.78▼$10.72$564.51M1.72.00 million shs4.07 million shsVECTVectivBio$16.85$16.85$4.25▼$16.98$573.24M0.11N/AN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCFennec Pharmaceuticals+3.00%+13.79%-4.77%-4.33%-32.28%IMTXImmatics+2.10%+12.73%+5.18%-8.63%-51.20%RLAYRelay Therapeutics-4.91%+5.80%+13.97%-30.80%-52.96%VECTVectivBio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFENCFennec Pharmaceuticals2.0311 of 5 stars3.61.00.00.02.72.50.0IMTXImmatics1.988 of 5 stars3.61.00.00.03.41.70.0RLAYRelay Therapeutics2.0004 of 5 stars3.41.00.00.02.02.50.6VECTVectivBioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCFennec Pharmaceuticals 3.25Buy$13.67126.27% UpsideIMTXImmatics 3.20Buy$16.67233.33% UpsideRLAYRelay Therapeutics 2.82Moderate Buy$18.36451.46% UpsideVECTVectivBio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FENC, IMTX, VECT, and RLAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025RLAYRelay TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$4.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/11/2025FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/10/2025FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$13.003/7/2025RLAYRelay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/27/2025RLAYRelay TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.002/27/2025RLAYRelay TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$27.00 ➝ $23.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCFennec Pharmaceuticals$47.54M3.51N/AN/A($0.43) per share-14.05IMTXImmatics$155.84M3.90N/AN/A$2.88 per share1.74RLAYRelay Therapeutics$10.01M56.41N/AN/A$5.90 per share0.56VECTVectivBio$27.34M20.97N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCFennec Pharmaceuticals-$16.05M-$0.06N/AN/AN/A-2.30%-53.38%-2.08%5/13/2025 (Estimated)IMTXImmatics-$104.98M$0.14N/AN/AN/A-47.94%-15.90%-9.38%5/13/2025 (Estimated)RLAYRelay Therapeutics-$341.97M-$2.39N/AN/AN/AN/A-45.75%-40.75%5/5/2025 (Estimated)VECTVectivBio-$93.74MN/A0.00∞N/AN/AN/AN/AN/ALatest FENC, IMTX, VECT, and RLAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025FENCFennec Pharmaceuticals-$0.12N/AN/AN/A$8.18 millionN/A5/13/2025Q1 2025IMTXImmatics-$0.39N/AN/AN/A$14.92 millionN/A5/5/2025Q1 2025RLAYRelay Therapeutics-$0.51N/AN/AN/A$0.01 millionN/A3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million2/26/2025Q4 2024RLAYRelay Therapeutics-$0.57-$0.45+$0.12-$0.45$5.53 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/AVECTVectivBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCFennec PharmaceuticalsN/A7.807.64IMTXImmaticsN/A3.983.98RLAYRelay TherapeuticsN/A18.4218.42VECTVectivBioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCFennec Pharmaceuticals55.51%IMTXImmatics64.41%RLAYRelay Therapeutics96.98%VECTVectivBioN/AInsider OwnershipCompanyInsider OwnershipFENCFennec Pharmaceuticals10.98%IMTXImmatics3.30%RLAYRelay Therapeutics4.32%VECTVectivBio9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCFennec PharmaceuticalsN/A27.59 million24.54 millionOptionableIMTXImmatics260121.55 million115.42 millionOptionableRLAYRelay Therapeutics330169.52 million160.15 millionOptionableVECTVectivBio3034.02 millionN/ANo DataFENC, IMTX, VECT, and RLAY HeadlinesRecent News About These CompaniesIronwood’s shares sink as FDA demands new trial for lead drugApril 15, 2025 | msn.comA brain biotech launches with Roche’s spare partsFebruary 13, 2025 | biopharmadive.comAravax Continues International Expansion with Appointment of Aled Williams as Chief Business OfficerJanuary 21, 2025 | markets.businessinsider.comCDR-Life Appoints Sarah Holland, PhD, as Chief Business OfficerDecember 5, 2024 | finance.yahoo.comRecent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBDNovember 12, 2024 | gut.bmj.comGraft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsightSeptember 23, 2024 | finance.yahoo.comEtherio Group: 2024 CMI 25September 21, 2024 | meetingsnet.comCompare with VectivBio Holding AG (VECT)May 29, 2024 | msn.comenGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of DirectorsMay 15, 2024 | finance.yahoo.comVicore Pharma Holding: Vicore Expands and Strengthens its Board of DirectorsMay 14, 2024 | finanznachrichten.deVicore Expands and Strengthens its Board of DirectorsMay 14, 2024 | finance.yahoo.comShort Bowel Syndrome Market by 2032: Forecast Report Estimates Significant GrowthApril 5, 2024 | uk.finance.yahoo.comFDA approves DMD treatment from ItalfarmacoMarch 31, 2024 | cen.acs.orgPipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpointsMarch 18, 2024 | msn.comIronwood Nabs Phase III Win, Still Sees Stock NosediveMarch 1, 2024 | biospace.comIronwood felled by mixed data in short bowel syndrome trialMarch 1, 2024 | pharmaphorum.comUPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage studyMarch 1, 2024 | msn.comIronwood's bowel disease treatment meets main goal in late-stage trialFebruary 29, 2024 | reuters.comWhy Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?February 29, 2024 | benzinga.comOnly two sleeps left until February 31!February 29, 2024 | ft.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFENC, IMTX, VECT, and RLAY Company DescriptionsFennec Pharmaceuticals NASDAQ:FENC$6.04 -0.15 (-2.42%) As of 04:00 PM EasternFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Immatics NASDAQ:IMTX$5.00 +0.13 (+2.67%) As of 04:00 PM EasternImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Relay Therapeutics NASDAQ:RLAY$3.33 +0.23 (+7.42%) As of 04:00 PM EasternRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.VectivBio NASDAQ:VECT$16.85 0.00 (0.00%) As of 04/25/2025VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
